Ichor’s Auctus Biologics closes quick $1.5MM

Posted on Posted in Uncategorized

Please click here for original article. LAFAYETTE, NY: Auctus Biologcs, Inc., a new portfolio company of Ichor Therapeutics, Inc., announced today the closure of $1.5MM in seed funding. The company will develop RPtag, a hyper-stable antibody mimetic scaffold published earlier this year in the peer-reviewed journal ACS Biochemistry, to take on conventional clinical antibody therapy […]

ESF, Ichor Therapeutics Team Up to Combat Age-related Illness

Posted on Posted in Uncategorized

View original article here. The State University of New York College of Environmental Science and Forestry (ESF) and Ichor Therapeutics are partnering to train graduate students in researching drugs that could combat age-related illnesses. The educational component will occur at ESF, where students will focus on biochemistry, chemistry or bioprocess engineering. Their laboratory research will […]

Ichor announces $1M life science strategic fund in Syracuse

Posted on Posted in Uncategorized

LAFAYETTE, NY: Today, Ichor Therapeutics, a biotechnology company that develops therapeutic interventions for age-associated disease, announced the formation of Grapeseed.Bio, a life science strategic fund and accelerator program. Through this program, life science entrepreneurs receive up to $100k in seed funding, technical training, full access to Ichor’s research laboratory, and mentorship in exchange for equity. […]

Ichor portfolio company Antoxerene closes $10MM deal with Juvenescence

Posted on Posted in Uncategorized

Read the original article here. July 12, 2018 LAFAYETTE, N.Y.–(BUSINESS WIRE)–Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., focused on small molecule drug discovery for pathways of aging, announced today the launch of a joint venture with Juvenescence Limited. The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence […]

Longevity Research Institute partners with Ichor to validate life extension compounds and regimens

Posted on Posted in Uncategorized

LaFayette, NY – Today the Longevity Research Institute, a non-profit organization that designs and funds animal studies to validate the anti-aging effects of promising compounds, announced the initiation of its first lifespan study, which will be conducted at Ichor Therapeutics. There are over 50 compounds and treatment regimens that have been reported to extend lifespan […]

Industry Leader Joins Ichor Therapeutics as Chief Medical Officer

Posted on Posted in Uncategorized

Syracuse, NY – Ichor Therapeutics, a pre-clinical contract research organization, recently announced the appointment of Cornelis (Cees) Hendrik Wortel MD, PhD to the position of Chief Medical Officer (CMO). Dr. Wortel brings over 25 years of experience to Ichor, having worked as a senior (bio) pharmaceutical executive for early stage and established companies, both nationally […]

Ship of Theseus, LLC initiates lifespan study at Ichor

Posted on Posted in Uncategorized

Philadelphia, PA and LaFayette, NY – Today, Ship of Theseus, LLC, a bioengineering company that focuses on stem cell therapies for aging and age-associated disease, announces the initiation of a murine lifespan study to be conducted at Ichor Therapeutics, Inc. This work will inform new targets for therapeutic intervention in aging. Ship of Theseus was […]

Ichor unveils orally bioavailable antibody-like scaffold in ACS Biochemistry

Posted on Posted in Uncategorized

LaFayette, NY – Today, a landmark biotechnology was published for the first time in the peer-reviewed journal ACS Biochemistry. The article, “RPtag as an orally bioavailable, hyper stable epitope tag and generalizable protein binding scaffold,” describes a foundational technology that could have huge implications in drug discovery, diagnostics, and clinical antibody therapy.

Ichor CEO delivers keynote at TriBeta Northeast Conference

Posted on Posted in Uncategorized

Fredonia, NY: Today, the State University of New York at Fredonia hosted the Northeastern District-3 Conference for TriBeta, the Biology Honor Society. Kelsey Moody, CEO at Ichor Therapeutics, delivered the keynote address. In the address, he discussed Ichor’s humble beginnings in a West Syracuse apartment, and encouraging pre-clinical results from the company’s age-related macular degeneration […]